PSN-375963

• Catalog No.: P0028
• CAS Number: 388575-52-8
• M. F.: C17H23N3O
• M. W.: 285.38402
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: 4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]pyridine
• IUPAC Traditional name: 4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]pyridine
• Synonyms: 4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridine

DATABASE IDS

• MDL Number: MFCD01829706
• CAS Number: 388575-52-8

PROPERTIES

• Empirical Formula (Hill Notation): C17H23N3O
• Purity: ≥98% (HPLC)
• Apperance: white to off-white powder
• Solubility: DMSO: >10 mg/mL
• Storage Temperature: -20°C
• German water hazard class: nwg

DETAILS

Description (English)

Biochem/physiol Actions
PSN-375963 is a GPR119 partial agonist. GPR119 is an orphan GPCR, expressed predominantly in pancreas and GI tract, that has been characterized. Its endogenous ligands are oleoylethanolamide (OEA) and oleoyl-lysophosphatidylcholine, lipid signaling molecules that regulate food intake and body weight. OEA decreases food intake, so GPR119 agonists are potential therapies for obesity. Initial studies showed that PSN-375963 has similar potency and partial efficacy compared to OEA. Further studies revealed that although OEA and PSN-375963 are GPR119 agonists, they have divergent effects on insulin secretion, calcium signaling, and cAMP production.

Description (简体中文)

Biochem/physiol Actions
PSN-375963 is a GPR119 partial agonist. GPR119 is an orphan GPCR, expressed predominantly in pancreas and GI tract, that has been characterized. Its endogenous ligands are oleoylethanolamide (OEA) and oleoyl-lysophosphatidylcholine, lipid signaling molecules that regulate food intake and body weight. OEA decreases food intake, so GPR119 agonists are potential therapies for obesity. Initial studies showed that PSN-375963 has similar potency and partial efficacy compared to OEA. Further studies revealed that although OEA and PSN-375963 are GPR119 agonists, they have divergent effects on insulin secretion, calcium signaling, and cAMP production.